Use of fomepizole (4-methylpyrazole) for acetaminophen poisoning: A scoping review.
4-Methylpyrazole
Acetaminophen
CYP2E1
Fomepizole
Hepatotoxicity
NAC
Journal
Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
28
01
2021
revised:
30
08
2021
accepted:
11
11
2021
pubmed:
18
11
2021
medline:
12
1
2022
entrez:
17
11
2021
Statut:
ppublish
Résumé
Acetaminophen (paracetamol, APAP) poisoning is a prominent global cause of drug-induced liver injury. While N-acetylcysteine (NAC) is an effective antidote, it has therapeutic limitations in massive overdose or delayed presentation. The objective is to comprehensively review the literature on fomepizole as a potential adjunct antidote for acetaminophen toxicity. A scoping review was performed using standardized search terms from inception through July 2021. Reports on fomepizole as a therapeutic adjunct for APAP toxicity span heterogeneous types of evidence. Eleven preclinical studies (in vitro and animal), fourteen case reports/series, and one human volunteer study were included. Fomepizole's action is mediated by inhibition of CYP2E1 to prevent oxidant stress generation, and inhibition of c-Jun N-terminal kinase (JNK) to decrease amplification of oxidant stress signaling to mitochondria. Studies have shown a reduction in oxidative metabolites likely by shunting metabolism away from CYP2E1 and a resultant decrease in liver injury in animals, independent of CYP2E1 interactions. Fomepizole has been linked to few adverse effects. Based on in vitro and animal studies, and bolstered by case reports, fomepizole likely offers benefit as an adjunct antidote for APAP toxicity, however this remains to be shown in a human trial. NAC remains the standard of care antidote, but given that fomepizole is approved and generally safe, it may be considered for APAP toxicity as off-label use by experienced clinicians, in rare circumstances associated with increased risk of hepatotoxicity despite standard NAC dosing. The marginal clinical benefit of fomepizole adjunct therapy beyond NAC monotherapy remains to be clearly defined, and routine use for APAP overdose is premature based on current evidence.
Identifiants
pubmed: 34785186
pii: S0378-4274(21)00880-8
doi: 10.1016/j.toxlet.2021.11.005
pii:
doi:
Substances chimiques
Antidotes
0
Acetaminophen
362O9ITL9D
Fomepizole
83LCM6L2BY
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-61Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors take full responsibility for the writing and content of this article and acknowledge that it has no conflict with this academic publication. This article was not prepared at any request and was not financially supported. Each author participated in the study as independent experts. The views and opinions expressed in the article are those of the authors.